Natera Reports Q4 Revenue of $660 Million, Up 39% Year-over-Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: NASDAQ.COM
- Revenue Growth: Natera anticipates Q4 2025 revenue of approximately $660 million, a 39% increase from $476 million in Q4 2024, indicating robust demand for its Signatera oncology test driving revenue expansion.
- Surge in Testing Volume: The company processed 233,300 oncology tests in Q4, a 55% year-over-year increase, reflecting record adoption in clinical minimal residual disease (MRD) testing despite fewer sample days.
- Annual Performance Exceeds Expectations: For the full year 2025, revenues are expected to total around $2.3 billion, a 35% increase from $1.7 billion in 2024, surpassing the top end of Natera's financial outlook by $40 million, showcasing stronger-than-expected market performance.
- Cash Flow Situation: Although cash inflows for Q4 were approximately $30 million, down from $46 million in Q4 2024, the total cash inflows for the year exceeded $100 million, indicating financial stability amid ongoing growth.
Analyst Views on NTRA
Wall Street analysts forecast NTRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 233.50 USD with a low forecast of 172.00 USD and a high forecast of 280.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 239.560
Low
172.00
Averages
233.50
High
280.00
Current: 239.560
Low
172.00
Averages
233.50
High
280.00
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
